The Human Leukocyte Differentiation Antigen workshop Ⅸ(HLDA9), held in Barcelona, Spain, in December 2010, as with previous HLDA Workshops, is to provide an invaluable and ongoing service to the scientific community. Those present at this meeting represent the efforts of more than 200 laboratories worldwide who have jeoined together that characterize more than 269 CD antigens.
HLDA9 will study a panel of monoclonal antibodies against B cell-associated molecules. Only monoclonal antibodies against known cloned molecules will be included in the panel. Thus, no unknown antibody blind panels will be carried out. Some antibodies against known CD molecules expressed on B cells will also be included in this panel. MAbs will be provided by both researches and companies. HLDA9 focused mainly on studying and validating mAbs against human cell-surface molecules expressed on B cells.
HLDA9 summarizes information about newly designated CD molecules expressed on B cells. The results of their expression analysis of a large panel of mAbs against B-cell-associated molecules on B-cell subsets and plasma cells and leukemias using flow cytometry is presented. An HLDA9 panel of mAbs was also tested against different subsets of dendritic cells and plasmaocytoid dendritic cells. A study characterizing the new molecule FcHL6 is also described herein.
|CD210||IL10R, CDW210A, HIL-10R, IL-10R1, IL10RA||Receptor for IL10|
|CD215||IL15RA||Receptor for IL15.|
|CD270||HveA, TR2, TNFRSF14||Receptor for CD258 and CD272.|
|CD307a||FCRL1||May function in B-cells activation and differentiation.|
|CD307b||FCRL2||May function in B-cells activation and differentiation.|
|CD307c||FCRH3, IFGP3, IRTA3, SPAP2, FCRL3||May function in B-cells activation and differentiation|
|CD307d||FCRH4, IGFP2, IRTA1, FCRL4||May function in B-cells activation and differentiation|
|CD307e||CD307, FCRH5, IRTA2, BXMAS1, PRO820, FCRL5||May function in B-cells activation and differentiation|
|CD351||FCA/MR, FKSG87, FCAMR||Fc receptor that binds IgM with high affinity and IgA with a 10-fold lower affinity|
|CD352||NTB-A, SLAMF6, LY108||Triggers cytolytic activity only in NK cells expressing high surface densities of natural cytotoxicity receptors|
|CD353||SLAMF8||Regulates macrophage function; may play a role in B cell lineage commitment|
|CD354||TREM-1||Stimulates neutrophil and monocyte-mediated inflammatory responses.Triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers|
|CD355||CRTAM||Interaction with CADM1 promotes NK cell cytotoxicity and IFN-gamma secretion by CD8+ cells in vitro as well as NK cell-mediated rejection of tumors expressing CADM3 in vivo|
|CD357||TNFRSF18, GITR||Receptor for TNFSF18|
|CD358||TNFRSF21||May activate NFkB and promote apoptosis. May activate JNK and be lymphocytes. involved in T-cell differentiation. Required for both normal cell body death and axonal pruning|
|CD360||IL-21R||Receptor for interleukin-21.|
|CD361||EVDB, D17S376, EVI2B|
|CD362||Syndecan-2, HSPG, SDC2||Cell surface proteoglycan that bears heparan sulfate|
|CD363||EDG1, S1P1, ECGF1, EDG-1, CHEDG1, S1PR1||adhesion, endothelial differentiation|
|CD364||dJ90K10.5, MGC45378, MSMBBP, PI16||Peptidase inhibitor 16|